Lockheed Martin Investment Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.35M | Buy |
91,790
+31,720
| +53% | +$2.62M | 0.27% | 70 |
|
|
2025
Q4 | $5.12M | Buy |
60,070
+6,490
| +12% | +$533K | 0.17% | 74 |
|
|
2025
Q3 | $4.17M | Sell |
53,580
-1,950
| -4% | -$152K | 0.15% | 81 |
|
|
2025
Q2 | $4.34M | Sell |
55,530
-3,850
| -6% | -$287K | 0.16% | 81 |
|
|
2025
Q1 | $4.3M | Sell |
59,380
-1,390
| -2% | -$99.5K | 0.18% | 78 |
|
|
2024
Q4 | $4.5M | Buy |
+60,770
| New | +$4.25M | 0.18% | 75 |
|
|
2023
Q4 | – | Sell |
-59,050
| Closed | -$4.49M | – | 151 |
|
|
2023
Q3 | $4.49M | Sell |
59,050
-83,370
| -59% | -$6.7M | 0.34% | 57 |
|
|
2023
Q2 | $13.4M | Sell |
142,420
-1,350
| -0.9% | -$117K | 0.77% | 36 |
|
|
2023
Q1 | $11.9M | Buy |
143,770
+116,580
| +429% | +$9.16M | 0.67% | 33 |
|
|
2022
Q4 | $2.03M | Sell |
27,190
-25,620
| -49% | -$1.97M | 0.13% | 82 |
|
|
2022
Q3 | $4.36M | Buy |
52,810
+19,100
| +57% | +$1.84M | 0.35% | 56 |
|
|
2022
Q2 | $3.21M | Sell |
33,710
-52,116
| -61% | -$5.4M | 0.22% | 72 |
|
|
2022
Q1 | $10.1M | Buy |
85,826
+25,790
| +43% | +$2.89M | 0.56% | 50 |
|
|
2021
Q4 | $7.78M | Hold |
60,036
| – | – | 0.42% | 58 |
|
|
2021
Q3 | $6.8M | Sell |
60,036
-61,990
| -51% | -$7.08M | 0.37% | 50 |
|
|
2021
Q2 | $12.6M | Sell |
122,026
-35,170
| -22% | -$3.32M | 0.66% | 38 |
|
|
2021
Q1 | $13.1M | Sell |
157,196
-53,570
| -25% | -$4.53M | 0.67% | 43 |
|
|
2020
Q4 | $19.2M | Buy |
210,766
+43,600
| +26% | +$3.62M | 0.99% | 18 |
|
|
2020
Q3 | $13.3M | Sell |
167,166
-18,450
| -10% | -$1.44M | 0.83% | 28 |
|
|
2020
Q2 | $12.8M | Buy |
185,616
+14,700
| +9% | +$1.04M | 0.85% | 29 |
|
|
2020
Q1 | $10.7M | Buy |
170,916
+126,900
| +288% | +$9.15M | 0.73% | 31 |
|
|
2019
Q4 | $3.42M | Sell |
44,016
-85,314
| -66% | -$6.66M | 0.18% | 62 |
|
|
2019
Q3 | $9.48M | Sell |
129,330
-66,090
| -34% | -$4.64M | 0.6% | 29 |
|
|
2019
Q2 | $12M | Buy |
195,420
+120,420
| +161% | +$7.28M | 0.55% | 50 |
|
|
2019
Q1 | $4.78M | Buy |
75,000
+38,700
| +107% | +$2.21M | 0.22% | 55 |
|
|
2018
Q4 | $1.85M | Buy |
36,300
+21,600
| +147% | +$1.09M | 0.09% | 55 |
|
|
2018
Q3 | $853K | Sell |
14,700
-20,550
| -58% | -$1.01M | 0.04% | 58 |
|
|
2018
Q2 | $1.71M | Hold |
35,250
| – | – | 0.08% | 54 |
|
|
2018
Q1 | $1.64M | Buy |
+35,250
| New | +$1.53M | 0.07% | 77 |
|
|
2017
Q4 | – | Sell |
-25,200
| Closed | -$918K | – | 133 |
|
|
2017
Q3 | $918K | Sell |
25,200
-46,500
| -65% | -$1.77M | 0.05% | 105 |
|
|
2017
Q2 | $2.83M | Buy |
71,700
+33,300
| +87% | +$1.22M | 0.16% | 75 |
|
|
2017
Q1 | $1.2M | Sell |
38,400
-3,600
| -9% | -$113K | 0.07% | 109 |
|
|
2016
Q4 | $1.31M | Sell |
42,000
-49,200
| -54% | -$1.59M | 0.11% | 84 |
|
|
2016
Q3 | $3.67M | Hold |
91,200
| – | – | 0.32% | 44 |
|
|
2016
Q2 | $3.03M | Buy |
+91,200
| New | +$3.12M | 0.3% | 52 |
|
Other funds holding EW
VCM
VPM
Lockheed Martin Investment Management's EW Position: Q1 2026 in Review
Lockheed Martin Investment Management increased its Edwards Lifesciences (EW) stake by 53% in Q1 2026, buying an estimated $2.62M and bringing the position to 91,790 shares worth $7.35M. The position accounts for 0.27% of the portfolio, ranked #70.
Lockheed Martin Investment Management first reported a position in EW in Q2 2016 and has held it in 35 quarters since. The position peaked at $19.2M in Q4 2020. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Lockheed Martin Investment Management held 91,790 shares of Edwards Lifesciences worth $7.35M as of Q1 2026.
- Lockheed Martin Investment Management bought 31,720 Edwards Lifesciences shares in Q1 2026, an estimated $2.62M.
- Edwards Lifesciences made up 0.27% of Lockheed Martin Investment Management's portfolio in Q1 2026, its #70 holding.
- Lockheed Martin Investment Management first reported a position in Edwards Lifesciences in Q2 2016 and has held it in 35 quarters since.
- Lockheed Martin Investment Management's Edwards Lifesciences position peaked at $19.2M in Q4 2020.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Lockheed Martin Investment Management's 13F filing for Q1 2026, filed 7 May 2026.